Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer

Arch Ital Urol Androl. 2016 Mar 31;88(1):72-3. doi: 10.4081/aiua.2016.1.72.

Authors

Johann De Bono¹, Liji Shen, Oliver Sartor

Affiliation

¹ Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton. johann.de-bono@icr.ac.uk.

PMID: 27072184
DOI: 10.4081/aiua.2016.1.72

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Humans
Male
Prostatic Neoplasms, Castration-Resistant / drug therapy*